BioMarin’s Brineura made available on NHS
The £500,000 per patient drug was deemed too costly for use in February 2018.
Read More
Tag: Batten
Brineura hit with NICE rejection
NICE is rejecting NHS funding for a £500,000-a-year drug to treat Batten disease on concerns over its long-term effectiveness.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
